Clinical trial
SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome…
NCT00409539 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00409539 |
|---|---|
| Title | SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS) |
| Official title | A 10-week Randomised, DB, PG, PC Phase 2 Study to Investigate the Extent of Symptom Relief and the Safety and Tolerability of SMP-986 (20, 40, 80 and 120 mg) Administered Once Daily for 8 Weeks to Patients With Overactive Bladder Syndrome |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Collaborators | Dainippon Sumitomo Pharma America Industry ICON Clinical Research ClinPhone, Inc. Covance PPD Development, LP |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Overactive Bladder Syndrome (OABS) |
| Intervention type | Drug |
| Interventions | Placebo, SMP-986 |
| Enrollment | 550 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Dec 11, 2006 |
| Last update posted | Dec 10, 2014 |
| Countries | Estonia, France, Germany, Latvia, Lithuania, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: